Cargando…

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study

BACKGROUND: Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gold, Ralf, Piani-Meier, Daniela, Kappos, Ludwig, Bar-Or, Amit, Vermersch, Patrick, Giovannoni, Gavin, Fox, Robert J., Arnold, Douglas L., Benedict, Ralph H. B., Penner, Iris-Katharina, Rouyrre, Nicolas, Kilaru, Ajay, Karlsson, Göril, Ritter, Shannon, Dahlke, Frank, Hach, Thomas, Cree, Bruce A. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363350/ https://www.ncbi.nlm.nih.gov/pubmed/35639197 http://dx.doi.org/10.1007/s00415-022-11166-z

Ejemplares similares

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
por: Cree, Bruce AC, et al.
Publicado: (2022)

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
por: Arnold, Douglas L, et al.
Publicado: (2022)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
por: Bigaud, Marc, et al.
Publicado: (2023)

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2022)

Siponimod for multiple sclerosis
Publicado: (2021)

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2021)

Siponimod ameliorates experimental autoimmune neuritis
por: Uchi, Takafumi, et al.
Publicado: (2023)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
por: Behrangi, Newshan, et al.
Publicado: (2019)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Does Siponimod Exert Direct Effects in the Central Nervous System?
por: Kipp, Markus
Publicado: (2020)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation
por: Gruchot, Joel, et al.
Publicado: (2022)

Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence
por: Hach, Thomas, et al.
Publicado: (2023)

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016)

Impact of siponimod on vaccination response in a randomized, placebo-controlled study
por: Ufer, Mike, et al.
Publicado: (2017)

Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models
por: Dietrich, Michael, et al.
Publicado: (2022)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
por: Giovannoni, Gavin, et al.
Publicado: (2018)

Case-Based fMRI Analysis after Cognitive Rehabilitation in MS: A Novel Approach
por: Hubacher, Martina, et al.
Publicado: (2015)

Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis
por: Brand, Rosa Margareta, et al.
Publicado: (2021)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
por: Hauser, Stephen L., et al.
Publicado: (2023)

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
por: Wolinsky, Jerry S., et al.
Publicado: (2018)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
por: Gajofatto, Alberto
Publicado: (2017)

Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis
por: Song, Yumeng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j1f6r63pga60spqhjhe9hook5s